Biton et al. (2018) also reported that TP53, STK11, and EGFR mutations represented the anti-PD-1 treatment efficacy in lung adenocarcinoma. NSCLC patients with STK11 mutation displayed chemotherapy resistance, while co-mutations with KRAS or TP53 modulated TIME of STK11-mutant NSCLC tumors and affected immunotherapy response (Malhotra et al., 2022). Additionally, NSCLC patients with EGFR/HER2 exon 20 insertions had a higher expression of PD-L1 and exhibited the sensitive to anti-PD-1/PD-L1 therapy (Chen X. et al., 2021). This evidence concerns the gene KRAS and non-small cell lung carcinoma.